ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,781 | -5.0% | 1,162 | -9.5% | 0.00% | – |
| Q2 2023 | $114,554 | +5.1% | 1,284 | +26.3% | 0.00% | – |
| Q1 2023 | $108,993 | +3.8% | 1,017 | +18.0% | 0.00% | – |
| Q4 2022 | $105,000 | +6.1% | 862 | -9.2% | 0.00% | – |
| Q3 2022 | $99,000 | +22.2% | 949 | +9.0% | 0.00% | – |
| Q2 2022 | $81,000 | +6.6% | 871 | +33.8% | 0.00% | – |
| Q1 2022 | $76,000 | -16.5% | 651 | -3.7% | 0.00% | – |
| Q4 2021 | $91,000 | -71.1% | 676 | -65.9% | 0.00% | -100.0% |
| Q3 2021 | $315,000 | +14.5% | 1,980 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $275,000 | +1.1% | 2,095 | -0.8% | 0.00% | 0.0% |
| Q1 2021 | $272,000 | -11.7% | 2,112 | +14.7% | 0.00% | 0.0% |
| Q4 2020 | $308,000 | +15.8% | 1,841 | +6.5% | 0.00% | 0.0% |
| Q3 2020 | $266,000 | +28.5% | 1,729 | +23.1% | 0.00% | 0.0% |
| Q2 2020 | $207,000 | +1781.8% | 1,405 | +1264.1% | 0.00% | – |
| Q1 2020 | $11,000 | – | 103 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |